Organon and Samsung Bioepis add ustekinumab biosimilar to Canada deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
June 18, 2026 6:00 AM EDTThe amended agreement deepens Organon and Samsung Bioepiss collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology.
To be launched in Canada in 2026
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)-- Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA®, Samsung Bioepiss biosimilar referencing STELARA® (ustekinumab).
This press release features multimedia. View the full release here:... More
